Guardant Health, Inc. (GH): Price and Financial Metrics


Guardant Health, Inc. (GH): $31.48

0.41 (+1.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GH POWR Grades

  • GH scores best on the Quality dimension, with a Quality rank ahead of 29.18% of US stocks.
  • GH's strongest trending metric is Momentum; it's been moving down over the last 177 days.
  • GH's current lowest rank is in the Momentum metric (where it is better than 1.07% of US stocks).

GH Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for GH is 2.58 -- better than 79.74% of US stocks.
  • GH's went public 4.32 years ago, making it older than just 20.59% of listed US stocks we're tracking.
  • With a price/sales ratio of 7.39, GUARDANT HEALTH INC has a higher such ratio than 83.95% of stocks in our set.
  • Stocks that are quantitatively similar to GH, based on their financial statements, market capitalization, and price volatility, are OCUL, GTHX, AAOI, EYPT, and WISA.
  • GH's SEC filings can be seen here. And to visit GUARDANT HEALTH INC's official web site, go to guardanthealth.com.

GH Valuation Summary

  • GH's price/earnings ratio is -5.4; this is 123.79% lower than that of the median Healthcare stock.
  • Over the past 52 months, GH's EV/EBIT ratio has gone up 25.1.

Below are key valuation metrics over time for GH.

Stock Date P/S P/B P/E EV/EBIT
GH 2023-01-20 7.5 19.5 -5.4 -7.4
GH 2023-01-19 7.5 19.5 -5.4 -7.4
GH 2023-01-18 7.6 19.7 -5.4 -7.4
GH 2023-01-17 7.4 19.1 -5.3 -7.3
GH 2023-01-13 7.2 18.7 -5.1 -7.2
GH 2023-01-12 7.3 18.8 -5.2 -7.2

GH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GH has a Quality Grade of C, ranking ahead of 48.47% of graded US stocks.
  • GH's asset turnover comes in at 0.158 -- ranking 71st of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows GH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.158 0.665 -0.174
2021-03-31 0.166 0.662 -0.187
2020-12-31 0.199 0.677 -0.197
2020-09-30 0.244 0.683 -0.205
2020-06-30 0.249 0.677 -0.147
2020-03-31 0.258 0.683 -0.108

GH Price Target

For more insight on analysts targets of GH, see our GH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $167.39 Average Broker Recommendation 1.27 (Strong Buy)

GH Stock Price Chart Interactive Chart >

Price chart for GH

GH Price/Volume Stats

Current price $31.48 52-week high $78.34
Prev. close $31.07 52-week low $24.63
Day low $30.59 Volume 1,001,500
Day high $31.88 Avg. volume 1,587,794
50-day MA $37.95 Dividend yield N/A
200-day MA $46.34 Market Cap 3.22B

Guardant Health, Inc. (GH) Company Bio


Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was founded in 2011 and is based in Redwood City, California.


GH Latest News Stream


Event/Time News Detail
Loading, please wait...

GH Latest Social Stream


Loading social stream, please wait...

View Full GH Social Stream

Latest GH News From Around the Web

Below are the latest news stories about GUARDANT HEALTH INC that investors may wish to consider to help them evaluate GH as an investment opportunity.

Guardant Health: Positive ECLIPSE Data Signals More Upside

Guardant Health recently reported positive data for its registrational ECLIPSE study. Click here for a full investment analysis of GH stock.

Seeking Alpha | January 20, 2023

Guardant Health, Royal Marsden Partner on Prospective Liquid Biopsy Trial in Early Colorectal Cancer

The study is evaluating the Guardant Reveal assay to guide chemotherapy treatment decisions following surgery for stage II to III colorectal cancer.

GenomeWeb | January 19, 2023

Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer

LONDON & PALO ALTO, Calif.--(BUSINESS WIRE)--TRACC Part C trial will use Guardant Reveal ctDNA blood test to evaluate opportunity to reduce unnecessary use of chemotherapy in colorectal cancer

Business Wire | January 19, 2023

Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal blood test to help guide treatment decisions in colorectal cancer

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is partnering with The Royal Marsden NHS Foundation Trust on Part C of its “Tracking mutations in cell free DNA to predict Relapse in eArly Colorectal Cancer” (TRACC) study, which will evaluate the use of circulating tumor DNA (ctDNA) to guide chemotherapy treatment decisions after curative-intent surgery in patients

Wallstreet:Online | January 19, 2023

Guardant Health, Inc.: Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal blood test to help guide treatment decisions in colorectal cancer

Trial will evaluate use of circulating tumor DNA to guide chemotherapy treatment decisions following surgery for stage II-III colorectal cancer patients based on test results for minimal residual …

Finanz Nachrichten | January 19, 2023

Read More 'GH' Stories Here

GH Price Returns

1-mo 15.74%
3-mo -36.40%
6-mo -37.91%
1-year -49.83%
3-year -60.17%
5-year N/A
YTD 15.74%
2022 -72.81%
2021 -22.39%
2020 64.93%
2019 107.87%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5813 seconds.